Assistant Professor
Oncology
Dr. Jennifer A. Woyach, MD
|
|
Give Review
Jennifer Woyach works in the field of Oncology. She studied medicine at The Ohio State University College of Medicine. She received 1 awards: "CMS Meaningful Use Stage 1 Certification". Jennifer Woyach is also published. She has 27 publications published. The lastest publication: "Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders.' Jennifer Woyach accepts Medicare.
Publications
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic Leukemia.
- Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders.
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic Leukemia patients.
- Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic Leukemia and small lymphocytic lymphoma.
- miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
- OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic Leukemia cells.
- A phase I trial of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic Leukemia.
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic Leukemia cells.
- PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates pre-clinical activity in CLL.
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic Leukemia (CLL).
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
- Impact of targeted therapy on outcome of chronic lymphocytic Leukemia patients with relapsed del(17p13.1) karyotype at a single center.
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
- Survival of the weak (signalers): anergy in CLL.
- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 To Induce Cytotoxicity and an Atypical NF-?B Response in Chronic Lymphocytic Leukemia Cells.
- Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic Leukemia: results of s...
- The B-Cell receptor signaling pathway as a therapeutic target in CLL.
- Outcome of patients with relapsed or refractory chronic lymphocytic Leukemia treated with flavopiridol: impact of genetic features.
- Chemotherapy: New FluCam combination therapy has familiar limitations.
- Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic Leukemia: long-term follow-up...
- Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
- Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive Disease.
- A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic Leukemia and small lymphocytic lymphoma.
- New therapeutic advances in the management of progressive thyroid cancer.
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic Leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Schools
Ohio State University College of Medicine
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1851515035 | |
| NPPES Provider LastName | WOYACH | |
| NPPES Provider FirstName | JENNIFER | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 39.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851515035 |
| Last Name Of The Provider | WOYACH |
| First Name Of The Provider | JENNIFER |
| View All |
Similar Doctors
|
|
Dr. Mark S. Collins, MD |
|
Dr. Arvinder S. Bhinder, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cassandra N. Grenade, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Otterson, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark D. Brownell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael A. Caligiuri, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Michael R. Grever, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David P. Carbone, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Robert D. Rupert Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lin Zhang, MD |
|
Dr. Sam L. Penza, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. David E. Symer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph J. Maly, MD |
|
Dr. Guido Marcucci, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tzu-Fei Wang, MD |